Dr. Scranton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1620 Tremont Street
Brigham And Womens Hospital Division Of Aging
Boston, MA 02120Phone+1 617-525-7631
Education & Training
- Naval Medical Center (Portsmouth)Residency, Internal Medicine, 1994 - 1997
- East Tennessee State University James H. Quillen College of MedicineClass of 1994
Certifications & Licensure
- MA State Medical License 2000 - 2018
Clinical Trials
- Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes Start of enrollment: 2004 Jul 01
- Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin Start of enrollment: 2005 Feb 01
Publications & Presentations
PubMed
- 27 citationsEffect of treating erectile dysfunction on management of systolic hypertension.Richard E. Scranton, Elizabeth V. Lawler, Marc F. Botteman, Subha Chittamooru, David R. Gagnon
The American Journal of Cardiology. 2007-08-01 - 165 citationsThe Association Between Statins and Cancer Incidence in a Veterans PopulationWildon Farwell, Richard E. Scranton, Elizabeth V. Lawler, Robert A. Lew, Mary Brophy
Journal of the National Cancer Institute. 2008-01-16 - 61 citationsStatin use and fracture risk: study of a US veterans population.Richard E. Scranton, Melissa Young, Elizabeth V. Lawler, Daniel H. Solomon, David R. Gagnon
Archives of Internal Medicine. 2005-09-26
Press Mentions
- Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective DisorderMay 9th, 2023
- Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDAJuly 27th, 2021
- Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other IndicationsJuly 19th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: